Other Species / Isoforms
  JAK2 (mouse)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
Y119-p
ILYRIRFyFPHWYCS
Upstream
2 0
Kinase, in vitro:
  • JAK2 (mouse)
JAK2 (human) VLYRIRFyFPRWYCS Y119-p
JAK2 (mouse) ILYRIRFyFPHWYCS Y119-p
JAK2 (rat) ILYRIRFYFPHWYCS Y119
Y134-p
GSSRTYRyGVSRGAE
Upstream
1 1
Treatment
  • Epo
JAK2 (human) GSNRAYRHGISRGAE H134
JAK2 (mouse) GSSRTYRyGVSRGAE Y134-p
JAK2 (rat) GSNRTYRYGVSRGAE Y134
K167
DFVHGWIKVPVTHET
1 0
JAK2 (human) DFVHGWIkVPVTHEt K167-sm
JAK2 (mouse) DFVHGWIKVPVTHET K167
JAK2 (rat) DFVHGWIKVPVTHET K167
T174
KVPVTHETQEECLGM
1 1
JAK2 (human) kVPVTHEtQEECLGM T174-p
JAK2 (mouse) KVPVTHETQEECLGM T174
JAK2 (rat) KVPVTHETQEECLGM T174
Y201-p
DQTPLAVyNSVSyKT
Upstream
Downstream
3 1
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • JAK2 (mouse)
Treatment
  • angiotensin
  • Epo
JAK2 (human) DQTPLAIyNSISYkT Y201-p
JAK2 (mouse) DQTPLAVyNSVSyKT Y201-p
JAK2 (rat) DQTPLAVYNSISYKT Y201
Y206-p
AVyNSVSyKTFLPKC
Upstream
2 1
Kinase, in vitro:
  • JAK2 (mouse)
Treatment
  • Epo
JAK2 (human) AIyNSISYkTFLPkC Y206
JAK2 (mouse) AVyNSVSyKTFLPKC Y206-p
JAK2 (rat) AVYNSISYKTFLPKC Y206
K207
VyNSVSyKTFLPKCV
0 1
JAK2 (human) IyNSISYkTFLPkCI K207-ub
JAK2 (mouse) VyNSVSyKTFLPKCV K207
JAK2 (rat) VYNSISYKTFLPKCV K207
K212
SyKTFLPKCVRAKIQ
0 1
JAK2 (human) SYkTFLPkCIRAKIQ K212-ub
JAK2 (mouse) SyKTFLPKCVRAKIQ K212
JAK2 (rat) SYKTFLPKCVRAKIQ K212
Y221-p
VRAKIQDyHILTRKR
Upstream
Downstream
14 6
JAK2 (human)
Y221-p
JAK2 (mouse)
Y221-p
JAK2 (rat)
Y221-p
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • JAK2 (mouse)
Putative in vivo kinases:
  • JAK2 (mouse)
Regulatory protein:
  • EPOR (human)
  • IRS1 (human)
  • IRS2 (human)
Treatment
  • AG490
  • apigenin
  • Epo
  • exercise training
  • GH
  • GM-CSF
  • IFN-gamma
  • PD98059
JAK2 (human) IRAKIQDyHILTRKR Y221-p
JAK2 (mouse) VRAKIQDyHILTRKR Y221-p
JAK2 (rat) VRAKIQDYHILTRKR Y221
K244-ub
IQQFSQCkATARNLK
0 2
JAK2 (human) IQQFSQCkATARNLK K244-ub
JAK2 (mouse) IQQFSQCkATARNLK K244-ub
JAK2 (rat) IQQFSQCKATARNLK K244
Y317-p
TEQDVQLyCDFPDII
Upstream
Downstream
1 1
Effects on Modified Protein
  • enzymatic activity, inhibited
Putative in vivo kinases:
  • JAK2 (mouse)
Treatment
  • Epo
  • IL-3
JAK2 (human) TEQDLQLYCDFPNII Y317
JAK2 (mouse) TEQDVQLyCDFPDII Y317-p
JAK2 (rat) TEQDLQLYCDFPDII Y317
Y372-p
FVSLIDGyyRLTADA
Upstream
Downstream
2 2
Effects on Modified Protein
  • enzymatic activity, induced
  • molecular association, regulation
  • phosphorylation
  • protein stabilization
Effects on Biological Processes:
  • signaling pathway regulation
  • transcription, induced
Treatment
  • Epo
JAK2 (human) FVSLIDGYYRLTADA Y372
JAK2 (mouse) FVSLIDGyyRLTADA Y372-p
JAK2 (rat) FVSLIDGYYRLTADA Y372
Y373-p
VSLIDGyyRLTADAH
Downstream
1 1
Effects on Modified Protein
  • phosphorylation
JAK2 (human) VSLIDGYYRLTADAH Y373
JAK2 (mouse) VSLIDGyyRLTADAH Y373-p
JAK2 (rat) VSLIDGYYRLTADAH Y373
Y382
LTADAHHYLCKEVAP
0 1
JAK2 (human) LTADAHHyLCKEVAP Y382-p
JAK2 (mouse) LTADAHHYLCKEVAP Y382
JAK2 (rat) LTADAHHYLCKEVAP Y382
K415-ub
FAISKLKkAGNQTGL
0 1
JAK2 (human) FAISKLKKAGNQTGL K415
JAK2 (mouse) FAISKLKkAGNQTGL K415-ub
JAK2 (rat) FAISKLKKAGNQTGL K415
Y423-p
AGNQTGLyVLRCSPK
Upstream
1 3
Treatment
  • Epo
JAK2 (human) AGNQTGLyVLRCSPK Y423-p
JAK2 (mouse) AGNQTGLyVLRCSPK Y423-p
JAK2 (rat) AGNQTGLYVLRCSPK Y423
Y435-p
SPKDFNKyFLTFAVE
Upstream
1 4
Treatment
  • Epo
JAK2 (human) SPKDFNKyFLTFAVE Y435-p
JAK2 (mouse) SPKDFNKyFLTFAVE Y435-p
JAK2 (rat) SPKDFNKYFLTFAVE Y435
K468-ub
EYNLSGTkRNFSNLK
0 1
JAK2 (human) EYNLSGTKKNFSSLK K468
JAK2 (mouse) EYNLSGTkRNFSNLK K468-ub
JAK2 (rat) EYNLSGTKRNFSSLK K468
S518
VFRTNGISDVQIsPt
1 1
JAK2 (human) VFRTNGVsDVPtsPT S518-p
JAK2 (mouse) VFRTNGISDVQIsPt S518
JAK2 (rat) VFRTNGVSDVQLsPT S518
I522
NGISDVQIsPtLQRH
0 1
JAK2 (human) NGVsDVPtsPTLQRP T522-p
JAK2 (mouse) NGISDVQIsPtLQRH I522
JAK2 (rat) NGVSDVQLsPTLQRH L522
S523-p
GISDVQIsPtLQRHN
Upstream
Downstream
4 22
JAK2 (human)
S523-p
Effects on Modified Protein
  • enzymatic activity, inhibited
  • phosphorylation
Putative in vivo kinases:
  • ERK1 (human)
  • ERK2 (human)
Treatment
  • EGF
  • Epo
  • GH
  • IFN-gamma
  • IL-3
  • phorbol_ester
  • U0126
JAK2 (human) GVsDVPtsPTLQRPT S523-p
JAK2 (mouse) GISDVQIsPtLQRHN S523-p
JAK2 (rat) GVSDVQLsPTLQRHN S523-p
T525-p
SDVQIsPtLQRHNNV
0 1
JAK2 (human) sDVPtsPTLQRPTHM T525
JAK2 (mouse) SDVQIsPtLQRHNNV T525-p
JAK2 (rat) SDVQLsPTLQRHNNV T525
Y570-p
VRREVGDyGQLHKTE
Upstream
Downstream
8 862
Effects on Modified Protein
  • enzymatic activity, inhibited
Kinase, in vitro:
  • JAK2 (mouse)
Putative in vivo kinases:
  • JAK2 (mouse)
Regulatory protein:
  • EPOR (human)
  • FCER1A (mouse)
  • FLT3 (mouse)
Treatment
  • Epo
  • GH
JAK2 (human) VRREVGDyGQLHETE Y570-p
JAK2 (mouse) VRREVGDyGQLHKTE Y570-p
JAK2 (rat) VRREVGDyGQLHETE Y570-p
K581
HKTEVLLKVLDkAHR
0 1
JAK2 (human) HETEVLLkVLDKAHR K581-ub
JAK2 (mouse) HKTEVLLKVLDkAHR K581
JAK2 (rat) HETEVLLKVLDKAHR K581
K585-ac
VLLKVLDkAHRNYSE
0 1
JAK2 (human) VLLkVLDKAHRNYSE K585
JAK2 (mouse) VLLKVLDkAHRNYSE K585-ac
JAK2 (rat) VLLKVLDKAHRNYSE K585
Y613-p
HKHLVLNyGVCVCGE
Downstream
1 0
Effects on Modified Protein
  • enzymatic activity, induced
JAK2 (human) HKHLVLNYGVCVCGD Y613
JAK2 (mouse) HKHLVLNyGVCVCGE Y613-p
JAK2 (rat) HKHLVLNYGVCVCGE Y613
K630
ILVQEFVKFGsLDTy
1 0
JAK2 (human) ILVQEFVkFGSLDTy K630-sm
JAK2 (mouse) ILVQEFVKFGsLDTy K630
JAK2 (rat) ILVQEFVKFGSLDTY K630
S633-p
QEFVKFGsLDTyLKK
Upstream
Downstream
1 0
Effects on Modified Protein
  • activity, inhibited
Effects on Biological Processes:
  • carcinogenesis, induced
  • signaling pathway regulation
  • transcription, inhibited
Putative in vivo kinases:
  • Nik (human)
JAK2 (human) QEFVkFGSLDTyLKK S633
JAK2 (mouse) QEFVKFGsLDTyLKK S633-p
JAK2 (rat) QEFVKFGSLDTYLKK S633
Y637-p
KFGsLDTyLKKNKNS
Upstream
Downstream
3 2
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • JAK2 (mouse)
Putative in vivo kinases:
  • JAK2 (mouse)
Treatment
  • Epo
  • IL-3
JAK2 (human) kFGSLDTyLKKNKNC Y637-p
JAK2 (mouse) KFGsLDTyLKKNKNS Y637-p
JAK2 (rat) KFGSLDTYLKKNKNS Y637
S668-p
MHFLEEKsLIHGNVC
Upstream
1 1
Treatment
  • Epo
JAK2 (human) MHFLEENTLIHGNVC T668
JAK2 (mouse) MHFLEEKsLIHGNVC S668-p
JAK2 (rat) MHFLEEKSLIHGNVC S668
K728
PECIENPKNLNLATD
0 1
JAK2 (human) PECIENPkNLNLATD K728-ub
JAK2 (mouse) PECIENPKNLNLATD K728
JAK2 (rat) PECIENPKNLTLATD K728
K762
SALDSQRKLQFYEDK
0 4
JAK2 (human) SALDSQRkLQFYEDR K762-ub
JAK2 (mouse) SALDSQRKLQFYEDK K762
JAK2 (rat) SALDSQRKLQFYEDK K762
Y790
LINNCMDYEPDFRPA
0 1
JAK2 (human) LINNCMDyEPDFRPS Y790-p
JAK2 (mouse) LINNCMDYEPDFRPA Y790
JAK2 (rat) LINTCMDYEPDFRPA Y790
Y813-p
NSLFTPDyELLTEND
Upstream
Downstream
9 4
Effects on Modified Protein
  • molecular association, regulation
Kinase, in vitro:
  • JAK2 (mouse)
Phosphatases, in vitro:
  • PTPRJ (human)
Putative upstream phosphatases:
  • PTPRJ (mouse)
Treatment
  • Epo
  • GH
JAK2 (human) NSLFTPDyELLTEND Y813-p
JAK2 (mouse) NSLFTPDyELLTEND Y813-p
JAK2 (rat) NSLFTPDYELLTEND Y813
Y868-p
GSVEMCRyDPLQDNT
Upstream
Downstream
4 2
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • JAK2 (mouse)
Phosphatases, in vitro:
  • PTPRJ (human)
Putative in vivo kinases:
  • JAK2 (mouse)
Putative upstream phosphatases:
  • PTPRJ (mouse)
Treatment
  • Epo
  • GH
JAK2 (human) GSVEMCRYDPLQDNT Y868
JAK2 (mouse) GSVEMCRyDPLQDNT Y868-p
JAK2 (rat) GSVEMCRYDPLQDNT Y868
K882
TGEVVAVKKLQHSTE
0 1
JAK2 (human) TGEVVAVkkLQHSTE K882-ub
JAK2 (mouse) TGEVVAVKKLQHSTE K882
JAK2 (rat) TGEVVAVKKLQHSTE K882
K883
GEVVAVKKLQHSTEE
0 1
JAK2 (human) GEVVAVkkLQHSTEE K883-ub
JAK2 (mouse) GEVVAVKKLQHSTEE K883
JAK2 (rat) GEVVAVKKLQHSTEE K883
K903
EREIEILKsLQHDNI
0 1
JAK2 (human) EREIEILksLQHDNI K903-ub
JAK2 (mouse) EREIEILKsLQHDNI K903
JAK2 (rat) EREIEILKsLQHDNI K903
S904-p
REIEILKsLQHDNIV
Upstream
1 7
Treatment
  • Epo
JAK2 (human) REIEILksLQHDNIV S904-p
JAK2 (mouse) REIEILKsLQHDNIV S904-p
JAK2 (rat) REIEILKsLQHDNIV S904-p
K912-ac
LQHDNIVkyKGVCyS
0 1
JAK2 (human) LQHDNIVKYkGVCYS K912
JAK2 (mouse) LQHDNIVkyKGVCyS K912-ac
JAK2 (rat) LQHDNIVKYKGVCYS K912
K912
LQHDNIVKyKGVCyS
1 0
JAK2 (human) LQHDNIVkYkGVCYS K912-sm
JAK2 (mouse) LQHDNIVKyKGVCyS K912
JAK2 (rat) LQHDNIVKYKGVCYS K912
Y913-p
QHDNIVkyKGVCySA
Upstream
Downstream
1 0
Effects on Modified Protein
  • enzymatic activity, inhibited
Effects on Biological Processes:
  • cell growth, altered
Kinase, in vitro:
  • JAK2 (mouse)
Regulatory protein:
  • EPOR (mouse)
Treatment
  • Epo
JAK2 (human) QHDNIVkYkGVCYSA Y913
JAK2 (mouse) QHDNIVkyKGVCySA Y913-p
JAK2 (rat) QHDNIVKYKGVCYSA Y913
K914
HDNIVkyKGVCySAG
1 0
JAK2 (human) HDNIVkYkGVCYSAG K914-sm
JAK2 (mouse) HDNIVkyKGVCySAG K914
JAK2 (rat) HDNIVKYKGVCYSAG K914
Y918-p
VkyKGVCySAGRRNL
Upstream
1 0
Kinase, in vitro:
  • JAK2 (mouse)
JAK2 (human) VkYkGVCYSAGRRNL Y918
JAK2 (mouse) VkyKGVCySAGRRNL Y918-p
JAK2 (rat) VKYKGVCYSAGRRNL Y918
Y931-p
NLRLIMEyLPyGSLR
Upstream
1 6
Kinase, in vitro:
  • JAK2 (mouse)
JAK2 (human) NLKLIMEyLPyGsLR Y931-p
JAK2 (mouse) NLRLIMEyLPyGSLR Y931-p
JAK2 (rat) NLRLIMEYLPYGSLR Y931
Y934-p
LIMEyLPyGSLRDyL
Upstream
1 1
Kinase, in vitro:
  • JAK2 (mouse)
JAK2 (human) LIMEyLPyGsLRDyL Y934-p
JAK2 (mouse) LIMEyLPyGSLRDyL Y934-p
JAK2 (rat) LIMEYLPYGSLRDYL Y934
S936
MEyLPyGSLRDyLQK
0 1
JAK2 (human) MEyLPyGsLRDyLQK S936-p
JAK2 (mouse) MEyLPyGSLRDyLQK S936
JAK2 (rat) MEYLPYGSLRDYLQK S936
Y940-p
PyGSLRDyLQKHKER
Upstream
1 1
Kinase, in vitro:
  • JAK2 (mouse)
JAK2 (human) PyGsLRDyLQKHKER Y940-p
JAK2 (mouse) PyGSLRDyLQKHKER Y940-p
JAK2 (rat) PYGSLRDYLQKHKER Y940
Y956
DHKKLLQYTSQICKG
0 2
JAK2 (human) DHIKLLQyTSQICKG Y956-p
JAK2 (mouse) DHKKLLQYTSQICKG Y956
JAK2 (rat) DHKKLLQYTSQICKG Y956
Y966-p
QICKGMEyLGTKRyI
Upstream
Downstream
3 5
Effects on Modified Protein
  • enzymatic activity, induced
Kinase, in vitro:
  • JAK2 (mouse)
Putative in vivo kinases:
  • JAK2 (mouse)
Treatment
  • Epo
  • GH
JAK2 (human) QICKGMEyLGTkRyI Y966-p
JAK2 (mouse) QICKGMEyLGTKRyI Y966-p
JAK2 (rat) QICKGMEYLGTKRYI Y966
Y972-p
EyLGTKRyIHRDLAT
Upstream
Downstream
3 1
Effects on Modified Protein
  • enzymatic activity, induced
  • phosphorylation
  • protein conformation
Kinase, in vitro:
  • JAK2 (mouse)
Putative in vivo kinases:
  • JAK2 (mouse)
Treatment
  • angiotensin_2
  • GH
JAK2 (human) EyLGTkRyIHRDLAT Y972-p
JAK2 (mouse) EyLGTKRyIHRDLAT Y972-p
JAK2 (rat) EYLGTKRYIHRDLAT Y972
K991
VENENRVKIGDFGLT
1 0
JAK2 (human) VENENRVkIGDFGLT K991-sm
JAK2 (mouse) VENENRVKIGDFGLT K991
JAK2 (rat) VENENRVKIGDFGLT K991
K999
IGDFGLTKVLPQDKE
0 1
JAK2 (human) IGDFGLTkVLPQDKE K999-ub
JAK2 (mouse) IGDFGLTKVLPQDKE K999
JAK2 (rat) IGDFGLTKVLPQDKE K999
Y1007-p
VLPQDKEyyKVKEPG
Upstream
Downstream
81 21
JAK2 (human)
Y1007-p
JAK2 (mouse)
Y1007-p
JAK2 (rat)
Y1007-p
Effects on Modified Protein
  • enzymatic activity, induced
  • protein degradation
  • ubiquitination
Effects on Biological Processes:
  • cell growth, induced
  • signaling pathway regulation
Kinase, in vitro:
  • Abl (human)
  • BCR-ABL1 (human)
  • JAK2 (mouse)
Putative in vivo kinases:
  • BCR-ABL1 (human)
  • JAK2 (human)
Regulatory protein:
  • AR (mouse)
  • BCR-ABL1 (human)
  • CDC42 (human)
  • EPOR (mouse)
  • Nik (human)
  • RHOA (human)
  • SH2-B-beta (mouse)
  • TLR3 (mouse)
Treatment
  • AG490
  • angiotensin_2
  • antibody
  • bacterial infection
  • CoCl2
  • EGF
  • Epo
  • GH
  • IL-3
  • IL-3_withdrawal
  • imatinib
  • isoproterenol
  • JAK2_inhibitor
  • JAK_inhibitor_I
  • leptin
  • mifepristone
  • MPA
  • MPTP
  • phenylephrine
  • PP2
  • TPO
JAK2 (human) VLPQDKEyyKVkEPG Y1007-p
JAK2 (mouse) VLPQDKEyyKVKEPG Y1007-p
JAK2 (rat) VLPQDKEyyKVKEPG Y1007-p
Y1008-p
LPQDKEyyKVKEPGE
Upstream
Downstream
78 19
JAK2 (human)
Y1008-p
JAK2 (mouse)
Y1008-p
JAK2 (rat)
Y1008-p
Effects on Modified Protein
  • enzymatic activity, induced
  • ubiquitination
Effects on Biological Processes:
  • carcinogenesis, induced
  • cell growth, induced
  • signaling pathway regulation
Kinase, in vitro:
  • Abl (human)
  • BCR-ABL1 (human)
  • JAK2 (mouse)
Regulatory protein:
  • AR (mouse)
  • BCR-ABL1 (human)
  • CDC42 (human)
  • cIAP1 (human)
  • EPOR (mouse)
  • Nik (human)
  • RHOA (human)
  • SH2-B-beta (mouse)
  • TRAF2 (human)
Treatment
  • AG490
  • angiotensin_2
  • antibody
  • CoCl2
  • EGF
  • Epo
  • GDC-0152
  • GH
  • hypoxia
  • IL-3
  • IL-3_withdrawal
  • imatinib
  • isoproterenol
  • JAK_inhibitor_I
  • leptin
  • mifepristone
  • MPA
  • MPTP
  • phenylephrine
  • PP2
  • PQA-18
  • TPO
JAK2 (human) LPQDKEyyKVkEPGE Y1008-p
JAK2 (mouse) LPQDKEyyKVKEPGE Y1008-p
JAK2 (rat) LPQDKEyyKVKEPGE Y1008-p
K1011
DKEyyKVKEPGESPI
1 0
JAK2 (human) DKEyyKVkEPGESPI K1011-sm
JAK2 (mouse) DKEyyKVKEPGESPI K1011
JAK2 (rat) DKEyyKVKEPGESPI K1011
K1011
DKEyyKVKEPGESPI
0 1
JAK2 (human) DKEyyKVkEPGESPI K1011-ub
JAK2 (mouse) DKEyyKVKEPGESPI K1011
JAK2 (rat) DKEyyKVKEPGESPI K1011
K1069
MRMIGNDKQGQMIVF
0 1
JAK2 (human) MRMIGNDkQGQMIVF K1069-ac
JAK2 (mouse) MRMIGNDKQGQMIVF K1069
JAK2 (rat) MRMIGNDKQGQMIVF K1069
K970
GMEyLGTKRyIHRDL
1 0
JAK2 (human) GMEyLGTkRyIHRDL K970-ub
JAK2 (mouse) GMEyLGTKRyIHRDL K970
JAK2 (rat) GMEYLGTKRYIHRDL K970